These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 28515943)

  • 21. A cost comparison of pembrolizumab: Fixed and weight-based dosing.
    Slee AL; Coutsouvelis J; Tong B; Poole S; Zalcberg J
    J Oncol Pharm Pract; 2024 May; ():10781552241255287. PubMed ID: 38780402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
    Hall E; Zhang J; Kim EJ; Hwang G; Chu G; Bhatia S; Reddy S
    Cancer Med; 2020 Mar; 9(6):2106-2112. PubMed ID: 31994335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A real-world data approach to determine the optimal dosing strategy for pembrolizumab.
    Jang A; Nakashima L; Ng T; Fung M; Jiwani S; Schaff K; Suess J; Goncalves R; Jang D; Kuik K; Labelle S; Pow A
    J Oncol Pharm Pract; 2021 Apr; 27(3):635-643. PubMed ID: 32539663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.
    Long GV; Tykodi SS; Schneider JG; Garbe C; Gravis G; Rashford M; Agrawal S; Grigoryeva E; Bello A; Roy A; Rollin L; Zhao X
    Ann Oncol; 2018 Nov; 29(11):2208-2213. PubMed ID: 30215677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
    Hamid O; Robert C; Ribas A; Hodi FS; Walpole E; Daud A; Arance AS; Brown E; Hoeller C; Mortier L; Schachter J; Long J; Ebbinghaus S; Ibrahim N; Butler M
    Br J Cancer; 2018 Sep; 119(6):670-674. PubMed ID: 30202085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.
    Goldstein DA; Gordon N; Davidescu M; Leshno M; Steuer CE; Patel N; Stemmer SM; Zer A
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
    Bayle A; Besse B; Annereau M; Bonastre J
    Eur J Cancer; 2019 May; 113():28-31. PubMed ID: 30965212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Follow up survey for implementation of fixed-dosing of monoclonal antibodies.
    Heinhuis KM; Beijnen JH; Hendrikx JJMA
    Int J Clin Pharm; 2020 Feb; 42(1):3-6. PubMed ID: 32026351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of pembrolizumab in patients with advanced tumors.
    van Vugt MJH; Stone JA; De Greef RHJMM; Snyder ES; Lipka L; Turner DC; Chain A; Lala M; Li M; Robey SH; Kondic AG; De Alwis D; Mayawala K; Jain L; Freshwater T
    J Immunother Cancer; 2019 Aug; 7(1):212. PubMed ID: 31395089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
    Shemesh CS; Chanu P; Jamsen K; Wada R; Rossato G; Donaldson F; Garg A; Winter H; Ruppel J; Wang X; Bruno R; Jin J; Girish S
    J Immunother Cancer; 2019 Nov; 7(1):314. PubMed ID: 31753029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
    Dubé-Pelletier M; Labbé C; Côté J; Pelletier-St-Pierre AA
    Oncologist; 2023 Nov; 28(11):969-977. PubMed ID: 37364568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
    Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
    Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system.
    Bryant AK; Lewy JR; Bressler RD; Chopra Z; Gyori DJ; Bazzell BG; Moeller JA; Jacobson SI; Fendrick AM; Kerr EA; Ramnath N; Green MD; Hofer TP; Vaishnav P; Strohbehn GW
    Lancet Oncol; 2024 Jun; 25(6):802-810. PubMed ID: 38821085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
    Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
    J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.
    Osawa M; Hasegawa M; Bello A; Roy A; Hruska MW
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):705-715. PubMed ID: 30666395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
    Wang CY; Sheng CC; Ma GL; Xu D; Liu XQ; Wang YY; Zhang L; Cui CL; Xu BH; Song YQ; Zhu J; Jiao Z
    Acta Pharmacol Sin; 2021 Aug; 42(8):1368-1375. PubMed ID: 33154554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.
    Proctor JR; Gartner EM; Gray TE; Davies RH
    Cancer Chemother Pharmacol; 2022 Nov; 90(5):399-408. PubMed ID: 36102999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
    Peer CJ; Heiss BL; Goldstein DA; Goodell JC; Figg WD; Ratain MJ
    J Clin Pharmacol; 2022 Apr; 62(4):532-540. PubMed ID: 34648187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.